Bolt Biotherapeutics Completes Prana Acquisition and Raises $120 Million
Bolt completed its stock-for-stock acquisition of Prana Therapies in October and closed a concurrent $120 million private placement. Prana’s PRA-216 is in Phase 2 across asthma, COPD and atopic dermatitis; a fourth study is planned, with proof-of-concept data expected beginning in Q2 2027.
Bolt completed its stock-for-stock acquisition of Prana Therapies in October and closed a concurrent $120M private placement. PRA-216 is in Phase 2 across asthma, COPD and atopic dermatitis; a fourth study is planned, with proof-of-concept data expected beginning Q2 2027.Material DetailsContext by…